Nextcure, Inc. (NXTC) — 8-K Filings

8-K Filings (16)

• NextCure, Inc. Files 8-K Report — Dec 19, 2025 Risk: low
  On December 19, 2025, NextCure, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delawar
• 8-K Filing — Nov 17, 2025
• NextCure, Inc. Reports Board Changes and Executive Compensation Updates — Aug 25, 2025 Risk: medium
  On August 21, 2025, NextCure, Inc. reported a change in its board of directors and executive compensation arrangements. The filing indicates the departure of ce
• NextCure, Inc. Files 8-K on Financials — Aug 7, 2025 Risk: low
  NextCure, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and exhibi
• NextCure, Inc. Files 8-K on Rights and Bylaws — Jul 14, 2025 Risk: medium
  On July 14, 2025, NextCure, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles of in
• NextCure, Inc. Files 8-K Report — Jul 10, 2025 Risk: low
  On July 10, 2025, NextCure, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is not announcing
• NextCure, Inc. Files 8-K on Shareholder Vote Matters — Jun 23, 2025 Risk: low
  NextCure, Inc. filed an 8-K on June 23, 2025, reporting on matters submitted to a vote of security holders as of June 20, 2025. The filing does not contain deta
• NextCure, Inc. Files 8-K: Material Agreement & Equity Sales — Jun 16, 2025 Risk: medium
  On June 13, 2025, NextCure, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also rep
• NextCure, Inc. Files 8-K Report — Apr 10, 2025 Risk: low
  On April 10, 2025, NextCure, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the filing of Financial Statements and Exhibit
• NextCure Faces Delisting Concerns — Feb 3, 2025 Risk: high
  NextCure, Inc. filed an 8-K on February 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule as of January 31, 2025. The comp
• NextCure, Inc. Files 8-K Report — Jan 10, 2025 Risk: low
  On January 10, 2025, NextCure, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific
• NextCure, Inc. Files 8-K Report — Dec 10, 2024 Risk: low
  On December 10, 2024, NextCure, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updat
• NextCure, Inc. Files 8-K Report — Dec 5, 2024 Risk: low
  On December 5, 2024, NextCure, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specif
• NextCure, Inc. Files 8-K Report — Nov 8, 2024 Risk: low
  On November 8, 2024, NextCure, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific
• NextCure, Inc. Files 8-K on Security Holder Vote Matters — Jun 21, 2024 Risk: low
  On June 20, 2024, NextCure, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware with
• NextCure CEO Departs; Interim CEO Appointed — Jun 18, 2024 Risk: medium
  On June 18, 2024, NextCure, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announced

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX